Could newborn screening provide a turning point in the natural history of cystinosis? Review the latest publication “Newborn Screening: Review of...
Read moreBy Cystinosis Research Network
March 31, 2022
Leadiant Biosciences, Inc. received communication from the FDA that they have approved the new Cystaran bottle and manufacturer. Please...
Read moreBy Cystinosis Research Network
February 28, 2022
Data from the AVROBIO Phase 1/2 investigational gene therapy for cystinosis was released today at WORLDSymposium in San Diego....
Read moreBy Cystinosis Research Network
February 9, 2022
A newly approved eye drop solution will expand treatment options for people living with cystinosis in Canada. Targeting corneal...
Read moreThe Cystinosis Research Network (CRN) is pleased to welcome two newly appointed leaders whose professional expertise, lived experience, and...
Read moreNews from Leadiant regarding new storage of Cystaran (cysteamine ophthalmic solution) 0.44%. Beginning December 22, 2025, shipments of Cystaran...
Read moreThe next phase of clinical development for the CF10 prodrug to treat cystinosis has been announced. The Cystinosis Foundation...
Read moreThe Neuromuscular Clinic at Massachusetts General Hospital (MGH) led by Dr. Reza Seyedsadjadi, is currently enrolling participants for a...
Read moreEmory University in Atlanta, Georgia, is actively recruiting for the Cohort 0 control groupin the CYStem clinical trial. While...
Read more